4//SEC Filing
Gray Nancy Ryan 4
Accession 0002001011-25-000098
CIK 0000886163other
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 4:45 PM ET
Size
13.2 KB
Accession
0002001011-25-000098
Insider Transaction Report
Form 4
Gray Nancy Ryan
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-07$66.19/sh+3,556$235,372→ 11,650 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-07−3,556→ 0 totalExercise: $66.19Exp: 2029-06-06→ Common Stock (3,556 underlying) - Sale
Common Stock
2025-11-07$205.45/sh−3,015$619,432→ 8,094 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-11-07−3,015→ 0 totalExercise: $73.57Exp: 2027-08-18→ Common Stock (3,015 underlying) - Sale
Common Stock
2025-11-07$205.45/sh−3,556$730,580→ 8,094 total - Exercise/Conversion
Common Stock
2025-11-07$73.57/sh+3,015$221,814→ 11,109 total
Footnotes (2)
- [F1]This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 06, 2020, at an exercise price of $113.5900 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
- [F2]This Option was previously reported as a Grant of 3,452 shares, which vested in full on August 18, 2020, at an exercise price of $126.2600 per share but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001714949
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 4:45 PM ET
- Size
- 13.2 KB